Cure Lab, Inc. submits a proposal entitled "DNA vaccine against epidemic and potentially pandemic influenza strains" in response to NIH Cooperative Research Partnerships for Influenza Product Development. This research will be conducted in collaboration with investigators from Harvard Medical School, Northeastern University, University of Arkansas and the University of Pittsburgh. The aim of the joint proposal is to create three novel families of vaccine adjuvants and to establish their most efficacious combination. This work continues the Partnerships in Adjuvant Development program at Cure Lab. With this program the company is complementing its expertise in vaccine development with chemical and biochemical advances of extramural scientists. Previously, Cure Lab established collaborations with MIT.